Key takeaway: Zim Laboratories Limited held its Q4 and FY26 Earnings Conference Call on May 20, 2026, where management provided updates on operational and financial performance. Dr. Anwar Daud, Chairman and Managing Director, reported substantial completion of CAPA implementation related to EU GMP remediation, with a recent positive regulatory re-inspection. The company faced revenue impacts from geopolitical disruptions in the MENA region, estimating a loss of approximately INR 20 crore. Despite these challenges, the core pharmaceutical business showed sequential growth. CFO Shyam Mohan Patro highlighted a total operating income of INR 1,053 million for Q4 FY26, with EBITDA at INR 134 million. Management emphasized ongoing investments in regulatory compliance and organizational capacity, with a focus on maintaining strong relationships with global customers. The call concluded with management expressing optimism for FY27, contingent on regulatory approvals and market stabilization.

Key takeaway: Zim Laboratories Limited held its Q3 & 9M FY26 Earnings Conference Call on February 13, 2026, where management provided updates on their EU-GMP remediation and CAPA implementation plan, emphasizing its importance for future growth. Dr. Anwar Daud, Chairman and Managing Director, reported steady performance in the pharma segment and improvements in operational metrics, with total operating income for the quarter at approximately INR 1,087 million. The company completed a preferential issue of around INR 35 crores to fund expansion and compliance initiatives. Management highlighted the addition of key leadership roles to strengthen organizational capabilities. The call included a Q&A session where management addressed investor concerns regarding product development timelines and market strategies, particularly for NIP and OTF products. Overall, management expressed optimism about future growth and compliance with regulatory standards.

Key takeaway: Zim Laboratories Limited's investor presentation for Q3 and 9MFY26 highlighted several key financial metrics. Total Operating Income for Q3FY26 reached ₹1,087 million, reflecting a 12.8% year-over-year growth. EBITDA stood at ₹145 million, a 9.1% increase from ₹133 million in Q3FY25, with EBITDA margins at 13.4%. However, for 9MFY26, Total Operating Income declined slightly by 0.4% to ₹2,691 million, and EBITDA decreased by 15.5% to ₹280 million. The company reported a Profit After Tax (PAT) of ₹44 million in Q3FY26, recovering from a loss in the previous quarter. The presentation also detailed investments in business expansion and regulatory filings, with a focus on R&D, which accounted for 8.6% of Total Operating Income in 9MFY26. Management noted a significant contribution from the pharma and nutraceutical segments, with exports comprising 88% of revenue in Q3FY26.